January 18, 2021 |
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
